Post-translational modifications to proteins play important roles in biological function, and alteration of these modifications according to cellular conditions is a sophisticated way to regulate protein activity. Glycosylphos phatidylinositol (GPI) is a glycolipid covalently attached to proteins, and it represents a post-translational modification that anchors proteins to the plasma membrane-called a GPIanchor. The GPI-anchor is conserved among all eukaryotes and more than 150 proteins of various functions are modified with a GPI-anchor. The GPI-anchor is essential for the growth of yeasts and some protozoans, and defects in GPI-anchors are associated with a number of human diseases. This review focuses on the recent progress and topics in mammalian GPI-anchor biosynthesis, structural remodeling and diseases associated with GPI-anchor dysfunction.
A. Introduction
The concept of a GPI-anchor was established in 1985. Prior to 1985, there were reports that certain surface proteins in mammals and trypanosomes were released by phosphatidylinositol-specific phospholipase C (PI-PLC), which indicated the presence of proteins anchored to the plasma membrane via phosphatidylinositol (PI) (1) (2) (3) (4) (5) . In 1985, a body of compositional and structural data on Torpedo (6) and human acetylcholinesterases (7), rat Thy-1 (8) and Trypanosoma brucei VSG (9,10) were reported, which established the presence of GPI-anchors. In 1988, the first complete GPI-anchor structures for T. brucei VSG (11) and rat Thy-1 (12) became available, and in 1989, the biosynthetic pathway of the T. brucei GPI-anchor was presented (13) . During the following decade, the partial and complete structures of GPI-anchors in more than 20 proteins were reported and these data revealed that the backbone structure is conserved (Fig. 1) . New findings circa 1990 on the biological (1) (2) (3) (4) (5) (6,7) (8) (9,10)
significance of GPI-anchored proteins (GPI-APs), such that (i) GPI-APs transduce signals in a GPI-specific manner (14) (15) (16) ; (ii) GPI-APs are transported to the apical side in polarized cells (17, 18) ; and (iii) GPI-APs tend to accumulate in specialized microdomains that are resistant to solubilization by non-ionic detergents (18, 19) , drew more attentions of many researchers. In the same period, the main pathology of paroxysmal nocturnal hemoglobinuria (PNH) whose main symptom is chronic red blood cell destruction (hemolysis) due to the defective surface expression of complement regulators CD59 and DAF (CD55) (20) (21) (22) was found to be a defect in GPI-anchor biosynthesis. This conclusion was based on the finding that CD59 and DAF are GPI-anchored proteins (23, 24) . In 1993, PIG-A was identified as the first gene involved in the GPI biosynthetic pathway. Furthermore, PIG-A was found to be responsible for PNH (25) (26) (27) (28) . In yeasts, the GPI-anchor is essential for growth because many proteins in the cell wall and plasma membrane are GPI-anchored. Studies on yeast GPI biosynthesis have revealed that the genes involved are conserved between yeasts and mammals, and such research has contributed significantly to our understanding of the GPI biosynthetic pathway (refer to excellent reviews (29, 30) ). In protozoans, the majority of surface proteins such as T. brucei VSG, whose analysis led to the discovery of the GPI-anchor, are GPI-anchored (31, 32 concept that GPI-APs can be expressed at higher densities than transmembrane proteins, or that protozoans can escape from host immune attack by rapidly removing surface proteins that are recognized as antigens by cleaving their GPI portion. The GPI biosynthetic pathway of T. brucei is very similar to those found in yeast and mammals (32) , and defects lead to lethality in the bloodstream form of the parasite. Since eukaryotic pathogens are dependent on GPI biosynthesis for survival (33) , inhibitors of GPI biosynthesis represent potential therapeutic agents against fungi and protozoans (34,35). Prokaryotes do not have a GPI-anchor, but interestingly, mycobacterium has phosphatidylinositol mannoside (PIM), which is structurally similar to the GPI-anchor, and its derivatives lipomannan (LM) and lipoarabinomannan (LAM) (36) (37) (38) . These are constructed by adding mannoses (and arabinoses) to PI, and the similarity to the GPI-anchor is supported by the fact that mannosyltransferases in these biosyntheses have been identified based on amino acid sequence similarities to PIG-M, a mannosyltransferase operating in the GPI biosynthetic pathway (39) . PIM, LM and LAM are constituents of the cell wall and essential for the survival of mycobacterium. Since they function to escape host immune attack (38, 40, 41) and tuberculosis represents a serious worldwide disease, studies are required to further elucidate the biosynthetic pathway in an effort to provide potential new drug targets. The mature synthesized GPI-anchor is attached to proteins as a post-translational modification that occurs in the endoplasmic reticulum (ER), resulting in GPI-APs. Genes involved in the biosynthesis of GPI and the attachment of GPIs to proteins are termed the PIG (phosphatidylinositol glycan) family of genes, whereas genes acting at later steps in structural remodeling and transport of GPI-APs are termed PGAP (post-GPI-attachment to proteins) genes (42) . Defective GPI biosynthesis in cells leads to an absence of GPI-APs, which may be due to the degradation of the proteins caused by ER quality control and/or the secretion through the secretory pathway following cleavage processes by proteases in the ER (43) (44) (45) (46) . A PIG-A gene knockout in mice removed all GPIAPs from the surface, resulting in embryonic lethality at a very early stage in development (47) . In contrast, knockout of PGAP1 or PGAP3 genes still led to the expression of GPI-APs on the cell surface but such knockouts affected localization, physical properties and the amount of GPI-APs through the wrong structural remodeling (48, 49) . Moreover, the PGAP1-knockout and PGAP3-knockout mice survived to different extents and showed different phenotypes (50) . Fig. 2 provides a schematic of the overall GPI biosynthetic pathway and structural remodeling of GPI-APs occurring along secretory pathway described below. (32) 
B. GPI-Anchor Biosynthesis by PIG-Genes
In this section, we will provide an overview and recent topics regarding the GPI biosynthesis; however, for more extensive details please refer to other reviews (30, 42, 51) . Since the first gene, PIG-A, was identified in 1993 (26) , more than 20 genes have been cloned and fall into the PIG gene group (Fig. 2) . Synthesis of the GPI-anchor is initiated by the addition of an N-acetylglucosamine (GlcNAc) to free PI, which is followed by deacetylation of GlcNAc, resulting in GlcN-PI. GlcN-PI on the cytosolic face then flip-flops into Biosynthesis is initiated by transfer of GlcNAc from UDP-GlcNAc to PI (step 1). First two steps take place on the cytoplasmic side of the ER, whereas later steps occur on the luminal side. Genes involved in each step are shown. GPI intermediates harboring red PI portion (steps 1 to 4) indicate that they are diacyl-form, whereas considerable amount of intermediates harboring alkyl-acyl chains (symbolized in black) appears in later steps, which proposes a new step for an exchange of the lipid part (step 5). This alkyl-acyl lipid donor is derived from peroxisome. Mannoses are transferred from DPM which is synthesized by DPM synthase composed of DPM1, DPM2 and DPM3. Mature GPI (H8) is finally attached to the omega (ω) site of separately synthesized proteins, which is catalyzed by GPI-transamidase complex, as a post-translational modification. The GPI portion of the resulting GPI-APs is further modified by PGAPs. PGAP1 and PGAP5 remove an acyl chain from the inositol and an EtN-P from the second mannose, respectively, in the ER. Then, GPI-APs are transported to the Golgi, where another structural remodeling, namely fatty acid remodeling, occurs. The replacement of an unsaturated fatty acid chain with a saturated one requiring by PGAP3 and PGAP2 allows GPI-APs to associate with lipid rafts that may be also formed in the Golgi. Finally, GPIAPs are transported to plasma membrane partly in raft-dependent manner and accumulate in lipid rafts, which endows GPI-APs unique characteristics for the behavior and signaling. Acquired defects of PIG-A in hematopoietic stem cells cause PNH, and impaired expression of PIG-M caused inherited GPI deficiency. the luminal side of the ER and the later biosynthetic steps are carried out in the lumen. After modification of the inositol in GlcN-PI with an acyl chain (generally palmitate) by PIG-W, three mannoses and three ethanolamine-phosphates (EtN-P) are added, which completes the biosynthesis of the GPIanchor. Since the mannoses represent the backbone of the GPI-anchor and as an EtN-P attaching to the third mannose (the third EtN-P) bridges the GPI-anchor with a protein via an amide bond, they are indispensable for the synthesis of GPI-APs. The EtN-P attached to the first mannose (the first EtN-P) acts as a side-chain. Loss of the first EtN-P drastically decreases the synthesis of GPI-APs and leads to the accumulation of a GPI-intermediate (52) . Surface GPIAPs are found to have both the first and third EtN-Ps attached, indicating that these two groups are functionally important. In contrast, an EtN-P attached to the second mannose (the second EtN-P) is usually absent from the surface GPI-APs. Consequently, the significance of the second EtN-P has been a long-standing question. However, a recent study based on the analysis of newly established mutant cells defective in the step catalyzing the removal of EtN-P from the second mannose revealed the significance of the second EtN-P in the sorting of GPI-APs and that the majority of GPI-anchors are modified with the second EtN-P before attachment to proteins (see below). Finally a mature GPI-anchor that has undergone at least ten synthesis steps is transferred to a protein by a GPItransamidase complex. Precursor proteins that are modified with a GPI-anchor have a GPI-attachment signal sequence at the C-terminus. The GPI-attachment signal sequence is not strictly conserved; rather this sequence is a structurally conserved ambiguous sequence. The sequence is composed from the C-terminus of 10−20 hydrophobic amino acids followed by ~10 hydrophilic amino acids and an amino acid called the omega-site (Fig. 2) (30, 53, 54) . Precursor proteins are cleaved and modified with the GPI-anchor at the omega site by GPI-transamidase. Therefore, it is not easy to deduce the presence of the GPI-attachment signal sequence and omega site from the amino acid sequence; however, there are a few programs that are available for this prediction (55) . The precursor proteins are believed to form transient intermediates with the GPI-transamidase via a thioester bond between the omega site and the catalytic site before the addition of the GPI-anchor. In defective GPI-anchor biosynthesis, the intermediates, if formed, are hydrolyzed due to the lack of the GPI-anchor and subsequently the processed protein may be secreted as a soluble form (46) .
A unique feature in GPI-anchor biosynthesis is that the glycosyltransferases are often complexes composed of multiple protein components. This contrasts the biosynthetic pathways of N-and O-glycosylation, in which each glycosyltransferases generally operates singly. PIG-A requires (52) (30,53,54) (55) (46) five other proteins (PIG-C, -H, -P, -Q and -Y) for the GlcNAc transferase activity, and PIG-M (transfers the first mannose) requires PIG-X for the mannosyltransferase activity. PIG-V (transfers the second mannose) is known to form an enzyme complex with Pga1p in yeast, yet the mammalian homologue has not been identified. Except for Pga1, all these components are known to be essential for the enzymatic activities of the complexes. Mannosyltransferases, PIG-M, -V, -B (transfers the third mannose) and -Z (transfers the fourth mannose and is essential for yeasts but not for mammals), utilize dolicholphosphate-mannose (DPM) as a donor substrate that is synthesized by a DPM synthase composed of DPM1, DPM2 and DPM3 (56, 57) . Most mannosyltransferases utilizing nucleotide-sugars as substrates have a DXD motif in the active site as revealed by crystallography. In contrast, the structures of the active sites of the mannosyltransferases utilizing dolichol-phosphate-mannose have not been determined, although they are classified into the GT-C superfamily based on common features, namely several transmembrane domains and a DXD-like motif in the first extracellular loop (58) .
A recent finding in the GPI biosynthetic pathway is an additional lipid remodeling that differs from fatty acid remodeling in GPI-APs that is mediated by PGAP genes and described in the next section. Most free PIs, from which GPI is synthesized, have di-acyl lipid chains (59,60), whereas considerable amounts of PIs in surface GPI-APs have 1-alkyl,2-acyl (alkyl-acyl) lipid chains (60, 61) , indicating that structural remodeling may occur to replace an acyl chain with an alkyl chain. The biological significance of alkyl-acyltype GPI-APs has not been clarified due to the absence of cells or animals defective in this step. Recent reports revealed that this remodeling takes place during GPI synthesis in the ER (60) and that the peroxisome is involved in the synthesis of alkyl chains utilized in this step (62) . GPI intermediates accumulated in various mutant cells enabled us to analyze the composition of lipid chains in each GPI intermediate. Detailed analysis of the intermediates using mass spectrometry revealed that most GlcNAc-PI and GlcN-PI accumulated in PIG-L and PIG-W mutant cells, respectively, and were di-acyl types. In contrast, GlcN-acyl-PI accumulated in DPM1 mutant cells due to a lack of DPM had considerable amounts of alkyl chains (60) , indicating the presence of a new step in which an acyl chain is replaced with an alkyl one most likely following the flip-flop of the intermediates into the luminal side of the ER. Since alkyl chains linked to glycerol have been reported to be synthesized only in the peroxisome, we tested whether alkyl-acyl type GPIs can be synthesized in mutant cells in which the peroxisome enzymes involved in the synthesis of alkyl-acyl glycerols are defective. The results showed that the peroxisome enzymes are indispensable for the synthesis of alkyl-acyl-type GPIs (62) . Since enzymes directly catalyzing (56, 57) (62) the replacement of an acyl chain with an alkyl one, except for the enzymes in peroxisome, are not known at present, it is speculated that this structural remodeling is executed by an enzyme with phospholipase C or D activity which replaces (phospho-)diacylglycerol with (phospho-)alkylacylglycerol. The identification of the enzyme will reveal the mechanism.
C. Structural Remodeling and Transport of GPI-APs Regulated by PGAP Genes
This section focuses on three events that occur in the ER and Golgi apparatus after proteins are modified with the GPI-anchor and that bring about structural remodeling of GPI-APs, which in turn affects their trafficking, cellular localization and function.
The first remodeling involves removal of the acyl chain, generally palmitate, from the inositol by PGAP1 in the ER (inositol deacylation in Fig. 2 ). The addition of this palmitate by PIG-W during GPI biosynthesis begs the question of why such palmitate has to be removed. In PIG-W defective cells, the steps of GPI biosynthesis after the PIG-W-mediated step, especially the addition of a terminal EtN-P to the third mannose, are impaired, and surface expression of GPI-APs is strongly reduced, indicating that the palmitate is recognized by and is critical for the enzymes that operate post-PIG-W (63). On the other hand, how important is the removal of the palmitate by PGAP1? Defective PGAP1 does not affect the amount of surface expression of GPI-APs in cultured cells (48) . Moreover, most CD59 and DAF on human red blood cells have this palmitate probably due to a decrease of PGAP1 activity (64) , indicating that the inositol deacylation is not always necessary. Nevertheless, most mice, if PGAP1 is knocked out in the whole body, die within a day following birth, and show otocephaly-like symptoms (50) . A very small population could survive without manifesting the apparent abnormality but showed growth retardation and males were essentially infertility. Their spermatozoa were normal in number and motility, but were unable to enter into the oviduct. In vitro, PGAP1-deficient spermatozoa showed weak attachment to the zona pellucida and a severely diminished rate of fertilization. Despite the only structural difference that wild-type GPI-APs are membrane anchored by two lipid chains whereas GPI-APs in PGAP1-knockout mice are anchored by three lipid chains, the precise mechanisms by which the defect of PGAP1 causes mice lethality, developmental defects and male infertility remain unclear. It was recently reported that abnormal modification and expression of Wnt proteins caused by the defect of PGAP1 is a possible mechanism for the onset of oto mice (65) . The genetic interaction between PGAP1 and Wnt genes was also reported in Ciona intestinalis (66) .
The second remodeling is replacement of an unsaturated
fatty acid chain with a saturated chain (fatty acid remodeling in Fig. 2 ) (49, 67) . This remodeling occurs in the Golgi. The majority of the GPI-anchor and GPI-APs that resided in the ER harbor an unsaturated chain at the sn-2 position of the PI portion such as an arachidonate (C20:4), as well as other phospholipids chains (59, 60) . Conversely, most lipid chains at the sn-2 of the cell surface GPI-APs are saturated stearic acid (C18:0) (31, (68) (69) (70) . PGAP3 is involved in the removal of an unsaturated lipid chain and PGAP2 is required for the addition of a saturated chain, but it is not strictly known whether they have enzymatic activities. This fatty acid remodeling is considered to be important for the biological functions of GPI-APs, because the characteristic that GPI-APs tend to accumulate in specialized microdomains, so called lipid rafts, is dependent on the fatty acid remodeling of GPIAPs (49) . Experimental evidence that GPI-APs accumulate in lipid rafts is based on whether they are fractionated into a detergent-resistant membrane fraction (DRM). In normal cells, most GPI-APs are fractionated into a DRM but in PGAP3-deficient cells most GPI-APs are fractionated into non-DRM, indicating that GPI-APs which are not subjected to fatty acid remodeling lose the ability to accumulate in lipid rafts (49) . Lipid rafts have the nature of Lo (liquid-ordered) phase, which is relatively stable and formed by compact accumulation of cholesterol, glycosphingolipids and phospholipids with straight saturated lipid chains (19, 71, 72) . As such GPI-APs with bending unsaturated lipid chains such as an arachidonate are not compatible with the nature of the Lo phase lipid rafts; therefore this explains why GPI-APs with defective fatty acid remodeling are not found in lipid rafts. The characteristic of GPI-APs to accumulate in lipid rafts is considered to be important in terms of signal transduction, spatial distribution and trafficking; however, clarification of the significance remains unresolved due to the difficulties in proving these observations experimentally. PGAP3-deficient cells should become a good model to analyze the significance. Several unresolved questions related to the lipid remodeling include whether PGAP2 and PGAP3 are catalytic enzymes, whether other factors are involved and how this machinery functions. The third GPI-anchor remodeling occurs in the glycan portion (glycan remodeling in Fig. 2) (73) . The glycan structure of the cell surface GPI-APs is the same as that of H7-form GPI, in which the first and third mannoses are attached with EtN-P, therefore, H7-form was considered to be a mature GPI-anchor (Fig. 2) . However, analysis of recently established mutant cells revealed that the H8-form GPI, which is produced by the addition of another EtN-P to the second mannose of H7-form GPI (the second EtN-P), but not H7 itself represents a mature GPI-anchor, and that the second EtN-P attached to the second mannose is removed by PGAP5 in the ER following the modification of proteins with the H8-form GPI- ( (73) anchor (73) . This indicates that the second EtN-P is attached and removed before and after the binding of the GPI-anchor to proteins, therefore, this system may function as a quality control checkpoint in the completion of the modification. At present, the biological significance of the addition of the second EtN-P catalyzed by PIG-G is not clear due to the absence of PIG-G-deficient cells. However, the analysis of mutant cells defective in PGAP5 revealed the importance of the second EtN-P in the efficient sorting of GPI-APs to the ER exit site (ERES) (73) . This report proved for the first time the significance of the glycan portion, which is highly conserved among all eukaryotes. The significance of the addition of the second EtN-P by PIG-G and the detailed functions of the glycan portion will be elucidated soon.
D. Diseases Caused by Defects in the GPI-Anchor
PNH is an acquired hematopoietic stem cell disorder in which clonal cells that are defective in PIG-A, the first enzyme in the GPI biosynthesis pathway, are expanded (27, 74, 75) . This results in chronic and sudden intravascular destruction (hemolysis) of red blood cells that lack CD59 and DAF (CD55), both are GPI-anchored complement regulator molecules, by hyper-sensitivity to complement. The reason why only the PIG-A gene is causal for PNH among ~30 genes essential for the synthesis of GPI is because the PIG-A gene is located on the X chromosome (27) . Therefore, one mutational hit is sufficient to cause a defect to the GPI-anchor which is in contrast to other genes that are located in autosomes and require two hits for the onset of the disease state. We are proposing a three-step model of PNH pathogenesis.
Step 1 involves the generation of a GPI-deficient hematopoietic stem cell by somatic mutation of the PIG-A gene.
Step 2 involves the immunological selection of GPI-deficient hematopoietic stem cells (76, 77) . In this step, GPI-deficient cells not only survive, they also proliferate much more frequently to compensate for anemia. This elevated proliferation rate might increase the chance that additional genetic mutations are acquired, which leads to Step 3, where a subclone bearing the growth phenotype is generated. We identified HMGA2 as the candidate gene for Step 3 (78) .
Since PIG-A knockout mice die in the very early embryonic stages, inherited diseases that completely lack the GPI-anchor were thought to be absent, but a recent report showed the presence of a novel disease that was caused by a partial GPI deficiency that was propagated by cousinmarriages (79) . The patients have a point mutation in the binding sequence of the Sp1 transcriptional factor in the promoter of PIG-M, the first mannosyltransferase-encoding gene. This point mutation severely reduces PIG-M expression and leads to venous thrombosis and seizures. Interestingly, sodium butyrate, an inhibitor of histone deacetylase, improved (27, 74, 75) (27) (76,77) (78) (79) the expression of PIG-M and the surface expression of GPIAPs, which caused complete cessation of intractable seizures (80) . New diseases caused by a deficiency of the GPI-anchor might be isolated in the future from patients who have similar symptoms but whose causal gene is not identified.
E. Closing Remarks
A quarter of a century has passed since the concept of the GPI-anchor was established and many genes involved in GPI-anchor biosynthesis have been identified. GPI-anchors undergo further structural remodeling even after the GPIanchor is attached to the protein as a post-translational modification, and this structural remodeling plays a key role in defining the functions of the GPI-APs, which have not been fully elucidated. Consequently, further research is required to fully understand the functions of GPI-anchors as well as to clarify the pathology of various diseases associated with a GPI-anchor deficiency. (80) 
